Podcasts about Jazz Pharmaceuticals

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a series of pivotal advancements and challenges shaping the industry landscape—ranging from scientific breakthroughs to regulatory maneuvers, all underscoring the sector's dynamic evolution. Novartis has made headlines with its investigational drug, Delpacibart Braxlosiran, which successfully met primary endpoints in a Phase 1/2 trial for treating Facioscapulohumeral Muscular Dystrophy (FSHD). This RNA therapy utilizes an antibody-oligonucleotide conjugate to target the DUX4 gene, a significant cause of FSHD. The promising results not only mark a potential therapeutic breakthrough for this debilitating neuromuscular disease but also highlight Novartis' commitment to innovative treatments in rare diseases. In parallel, Enliven Therapeutics has reported positive outcomes from a Phase 1 trial of ELVN-001 for patients with Chronic Myeloid Leukemia (CML), who are heavily pretreated. This small molecule tyrosine kinase inhibitor shows improved efficacy, offering hope for those who have exhausted existing treatment options. As ELVN-001 progresses into later-stage trials, it may significantly enhance therapeutic options and outcomes for CML patients. Regulatory activities remain at the forefront, exemplified by Amgen's engagement with the Duke Clinical Research Institute to defend Tavneos amid an FDA push for market withdrawal. This illustrates the intricate complexity of regulatory processes and the importance of evidence-based advocacy in preserving access to critical therapies. In another regulatory development, Guardant Health's Guardant360 CDx has received FDA approval as a companion diagnostic for Boehringer Ingelheim's Hernexeos targeting HER2-mutant non-small cell lung cancer. The approval emphasizes the growing significance of liquid biopsy technologies in personalized oncology care, offering precise and less invasive diagnostic solutions. In business development news, strategic collaborations are gaining momentum. Simcere Pharmaceutical has partnered with Stanford Medicine to develop first-in-class therapies for Idiopathic Pulmonary Fibrosis. Meanwhile, Ildong Pharmaceutical and Welt are joining forces to create AI-driven digital therapeutics. These alliances reflect an increasing trend towards integrating cutting-edge technology and cross-disciplinary expertise to accelerate drug discovery and development. Funding dynamics within the sector are evolving, as seen with Neion Bio's successful Series A fundraising of $23 million aimed at enhancing its biologics manufacturing platform. Similarly, Human Continuum secured $5.13 million to advance its exosome-based regenerative medicine platform. These investments underscore a strong focus on innovative platform technologies promising to transform therapeutic modalities and manufacturing processes. Not all news is positive, however; Jazz Pharmaceuticals and PharmaMar faced setbacks as their Phase 3 trial for Zepzelca (Lurbinectedin) failed to meet its overall survival endpoint in metastatic small cell lung cancer. This highlights the inherent challenges in oncology drug development and underscores the need for continuous innovation. Regulatory hurdles persist as well, evidenced by Camurus receiving a second complete response letter from the FDA regarding Oclaiz (Octreotide) due to manufacturing concerns. The industry is also navigating cybersecurity challenges, as seen with Novo Nordisk's recent data breach incident. This breach underscores vulnerabilities within biopharma companies concerning intellectual property and patient data protection. It serves as a stark reminder of the necessity for robust cybersecurity measures to safeguard sensitive information critical to clinical trials and corporate integrity. Meanwhile, strategic planning remains essential as Astellas confronts a looming $6 billion patent cliff with Xtandi, its prostate cancer drug. The company's five-year strategy focuses on cost savings while sustaining innovation and competitiveness amidst impending revenue declines. The biotechnology sector continues to thrive amidst these challenges, evidenced by record levels of initial public offerings (IPOs). Despite broader economic uncertainties, investor confidence remains robust, highlighting biotech's potential for groundbreaking advancements and lucrative returns. Finally, artificial intelligence is making significant strides across health agencies, with a reported 148% increase at the FDA by 2025 alone. This surge in AI integration highlights its transformative potential in regulatory processes and healthcare delivery—offering opportunities to enhance efficiency and decision-making within the sector. In summary, today's developments encapsulate the vibrant pharmaceutical and biotech industries characterized by scientific innovation, regulatory intricacies, strategic collaborations, and financial maneuvers. These advancements offer new hope for patients while navigating complex landscapes that demand continuous innovation and compliance—a balance that defines success in this ever-evolving sector.Support the show

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

This podcast will give you an approach to neonatal seizures. In this episode, listeners will learn 1) how to describe the clinical presentation of different type of neonatal seizures, 2) recognize that neonatal seizures can present similar to non-epileptic neonatal behaviours and be able to contrast seizure presentations from non-epileptic behaviour, 3) Identify the risk factors that predispose neonates to seizures, 4) Describe common causes of seizures in the neonate, 5) Identify the different investigations to employ when working up a neonate for seizures, and 6) Discuss treatment options for neonatal seizures. This podcast was created by Gurleen Cheema, a third-year medical student at the University of Toronto, in collaboration with Dr. Lauren Sham, a pediatric neurologist and epileptologist and the Medical Director of the Tuberous Sclerosis Complex Program at SickKids Hospital in Toronto, Canada.  An author of this podcast has financial support from LivaNova and Jazz Pharmaceuticals.

Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here. Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CQN865. CME/AAPA/IPCE credit will be available until June 21, 2027.ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CQN865. CME/AAPA/IPCE credit will be available until June 21, 2027.ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CQN865. CME/AAPA/IPCE credit will be available until June 21, 2027.ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CQN865. CME/AAPA/IPCE credit will be available until June 21, 2027.ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CQN865. CME/AAPA/IPCE credit will be available until June 21, 2027.ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CQN865. CME/AAPA/IPCE credit will be available until June 21, 2027.ADAPT to Advance in ALL/LBL: Achieving Durable Asparaginase Exposure With Personalized Treatment in Pediatric and AYA Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

He's not going the wrong way, he's just going HIS way! In this episode of Talk About It, Greg sits down in studio with Loren Zitomersky - A.K.A. the "Backwards Guy." Loren has gained a ton of publicity over the years for attempting to break the world record for fastest marathon run backwards, and he does it all in the name of raising awareness for epilepsy! Before he was born, Loren's dad had a son who tragically died due to SUDEP, so he has devoted his athletic life to his brother's memory. Collectively, he has done over 80 interviews or televised segments with Inside Edition, the Boston Globe, Runner's World, the Associated Press, as well as various local and international news outlets, and has raised hundreds of thousands of dollars for epilepsy research! In addition to being Backwards Guy, he also runs a very popular social media channel called The Legal Beef. From his exdperience as a corporate lawyer, Loren is now harnessing his knowledge and expertise to provide the public with legal breakdowns and advice from viral social media clips. Naturally, his passion for epilepsy advocacy was eventually going to find its way into this venture, so we are so excited to be partnering with Loren on a series of short videos he produces for Talk About It on caregivers and epilepsy-related legal questions! Go to our website at TalkAboutIt.org to find those short clips. Know your rights, and also know that when you feel like you are going backwards sometimes, you're still moving forwards in the big picture. Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals. 

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

She sings! She acts! She hosts the epilepsy walk! She is a WARRIOR! This week on Talk About It, Greg sits down with a guest who is SO overdue for an interview that we can't believe she hasn't been on yet! Audrey Kaller is a singer and an actress who is racking up quite an impressive stretch in her young career with a brand new single, "Mood Swing Lover" coming out alongside a great performance on ABC's The Rookie debuting this weekend. What is most impressive, though, is that she is relentless in talking openly about her epilepsy diagnosis, and advocating everywhere she goes for seizure first aid and awareness. Audrey recalls her journey with epilepsy from the age of 13, when she had her first grand mal seizure at her friend's bat mitzvah, and into college when her sorority sisters abandoned her on the front lawn during an episode where she was having multiple seizures that risked her life. Additionally, we hear her brand new single in FULL, and Greg recaps the incredible Walk for Epilepsy that just happened at the Rose Bowl in Pasadena, hosted by Audrey! Team Talk About It! was out there and we hear from an inspiring young couple whose infant son was diagnosed with epilepsy. This is a packed episode, and you don't want to miss a minute of it! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals. 

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the current treatment landscape for frontline HER2-positive gastroesophageal junction (GEJ) and gastric cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we welcome Dr. Sunnie Kim from the University of Colorado and Dr. Samuel Cytryn from Memorial Sloan Kettering, who shared their insights on the latest advancements in HER2-targeted therapies. We discussed the pivotal TOGA and KEYNOTE-811, the promising data from the HERIZON-GEA01 study featuring Zanidatamab, and the implications of these findings for clinical practice. Key topics included: Current standard of care for HER2-positive GEJ and gastric cancer The role of PD-L1 status in treatment decisions Mechanisms and efficacy of Zanidatamab compared to traditional therapies Management of side effects, including diarrhea and infusion-related reactions Future directions in HER2-targeted therapies, including T-DXd based on the DESTINY Gastric-04 trial Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/new-precision-strategies-for-her2-gea-interpreting-new-data-to-inform-clinical-practice

When life is leaving you with so many questions, especially when you are dealing with an epilepsy diagnosis, sometimes it is good to hear some answers from someone with experience. Good thing we have our in-house expert, Greg Grunberg, to answer the call! Welcome to the final chapter of our two-part series in which Greg answers the top 20 questions that have come from the epilepsy community. While he says he might not have all the answers, he speaks from his heart after nearly 30 years of being a caregiver to his son with epilepsy, and he is here to assure you that it is going to be okay. We don't know what version of okay that might look like, but it certainly be okay. It is not wrong to ask questions, or be frustrated, or have the feeling that you want to give up. The best thing to do when that happens is to... you guessed it... talk about it! In this part 2, Greg takes on questions about making jokes about epilepsy, what to do about treatment not working, SUDEP, protecting a child with epilepsy vs letting them make mistakes or risk danger, and so much more. This is real stuff, these are real feelings, and Greg has the real answers.  We would love to hear your perspective. If you have ideas, or agreements, even disagreements with Greg, let us know! Comment, share, and let's keep the conversation going. The first step is ALWAYS to talk about it! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Get ready to Talk About It! Or in Greg's case, answer about it! In this two-part series, Greg takes on your 20 most-asked questions and responds from the heart, giving authentic insight from an epilepsy advocate and caregiver. In this part 1, we cover some of the heavy questions that weigh on patients and caregivers, from "why me?" to "what can I do about caregiver burnout?" Social isolation, disagreements among parent caregivers, driving safety, refusal to take meds - these are all things that patients and caregivers have to confront head-on, and Greg is here to provide a steady voice in the conversation for you. We always say on this show, "everybody has something" and remind you that epilepsy doesn't define your life. But that doesn't mean that these questions aren't coming from real emotions and frustrations, or that it is wrong to ask altogether. The first step in finding answers, or at least dealing with the emotions behind the questions, is to talk to other people about it. Greg might not have all the answers, but he certainly speaks from his heart. Give this episode a listen and let us know if you agree or disagree - even disagreements lead to talking about it! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

We here at Talk About It are so excited about our expansion into helping raise awareness for conditions that are related to epilepsy. One of the conditions at the top of our list is autism spectrum disorder. Did you know that approximately 25-30% of children with ASD will develop epilepsy in their lifetime? But not only are these conditions medically correlated, they also share similarities when it comes to bullying, stigma, job prospects, dating, and everyday life experience. That means, of course, we need to TALK ABOUT IT! Greg sits down in studio with his good friend Holly Robinson Peete, an actress who has lit up our screen since her breakout role in 21 Jump Street in 1987 and has gone on to star in so many of our favorite movies and shows. Together with her husband, former NFL quarterback and Heisman trophy candidate Rodney Peete, they started the HollyRod Foundation to help families battling a Parkinson's diagnosis, but expanded into autism after their eldest son RJ, a twin, was diagnosed with autism spectrum disorder. The foundation helps to provide medical, financial, and emotional support for families affected by these conditions.  With the guidance and support of his amazing parents, RJ has defied the odds to overcome all of the "nevers" - never saying he loves them, never getting a quality education, never being able to socialize, never being able to hold a job - a stigma that still plagues families dealing with this disorder, and increasingly being mainstreamed by people in power. RJ now is a clubhouse attendant for the Los Angeles Dodgers, and an integral part of their team's family dynamic. Holly and Greg discuss his role on the team, the bullying that their family went through, dating on the spectrum, and the importance of job placement for those with spectrum disorders. This is such a heartwarming episode and you will learn so much! Don't miss it! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Sit... Stay... Talk about it! This incredible episode is all about our very best friends, and the most adorable heroes of the epilepsy community, dogs! Greg chats with Katie Gonzalez, founder of Little Angels Service Dogs. LASD is a nonprofit that trains incredible canine candidates and passes the graduates on to families in need of a service dog for so many medical conditions, from seizure alert to autism help, mobility assistance, diabetes, stress and anxiety disorders, and so many more.  In this part 1 (part 2 is coming soon where Greg will go to the center and see the training in action), they talk about the dogs' incredible ability to detect an oncoming seizure by smelling chemical changes in a person's body. Katie has not only dedicated her life to training these incredible animals, but also to the science behind these chemical changes and how dogs can detect it. She even wrote the book - literally - on training your service dog based on this research!  Plus, Greg asks general questions about best practices when it comes to our good boys and good girls, and Greg and Nick battle over who has the cuter dog. Do not miss this episode, otherwise you won't get your treat! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest innovations, strategic shifts, and regulatory updates shaping the industry.Johnson & Johnson's Tecvayli, a promising monotherapy for multiple myeloma, has shown remarkable efficacy in clinical trials. By reducing the risk of disease progression or death by 71% among patients resistant to anti-CD38 therapies, Tecvayli is setting a new standard in oncological treatment. This breakthrough underscores not only its potential as a standalone therapy but also highlights significant advancements in managing multiple myeloma—a cancer notoriously difficult to treat and manage.In regulatory developments, Sanofi has recently completed pricing negotiations with U.S. policymakers, gaining much-needed clarity on drug pricing regulations. However, Sanofi remains cautious as evolving policies could impact future operations. This scenario is emblematic of the broader industry challenge: navigating an uncertain regulatory landscape while maintaining stability and profitability in volatile markets.Astellas Pharma is adapting to its looming patent cliff for the prostate cancer drug Xtandi by focusing on innovation as a strategy for sustainable growth. With patent protection set to expire next year, Astellas emphasizes innovation over acquisitions for revenue protection, reflecting a broader industry trend towards long-term growth strategies rather than short-term gains.Meanwhile, Jazz Pharmaceuticals has sold a priority review voucher for $200 million, highlighting the persistent value of these vouchers which expedite FDA review processes. Such vouchers are becoming essential strategic assets as companies seek competitive advantages through faster market entry.On the technological front, Becton Dickinson's $110 million investment to expand syringe production capabilities demonstrates efforts to meet rising demand for injectable medications like GLP-1s. This initiative not only addresses immediate supply chain needs but also aligns with broader discussions about reshoring pharmaceutical manufacturing in the U.S., enhancing domestic production capabilities.Financially, strategic trends were a focal point at the recent J.P. Morgan Healthcare Conference. Although large-scale mergers and acquisitions were anticipated, none materialized, suggesting an evolving focus towards strategic partnerships and incremental innovations over mega-mergers among industry stakeholders.Looking ahead, AbbVie's projection of strong growth into the 2030s is driven by a robust pipeline and strategic initiatives. As companies navigate a complex landscape defined by innovation demands and regulatory changes, such outlooks underscore the industry's commitment to sustaining growth and innovation while improving patient outcomes through novel treatments and technologies.Italian pharmaceutical company Alfasigma's acquisition of rights to an injectable treatment for HSV encephalitis from a German biotech firm further exemplifies strategic investments aimed at expanding therapeutic portfolios with innovative solutions addressing critical health needs. This move is significant given the limited therapeutic options available for this severe condition.The Novo Nordisk Foundation's $860 million investment in Denmark's BioInnovation Institute underscores efforts to strengthen local biotech ecosystems. By nurturing homegrown biotech and deep tech companies, this initiative positions Denmark as a prominent hub for research and development while facilitating the translation of scientific discoveries into viable therapeutic solutions.Ocugen's promising mid-phase data for its gene therapy targeting eye disease positions it as a potential competitor against market leaders like Apellis and Astellas. The positive phase 2 results highlight gene therapy's growiSupport the show

Happy New Year from all of us at Talk About It! In this special to kick off the new year, Greg and Nick take a look back at some of the best moments that sparked conversation in 2025 and reflect on what could be learned from them. It was incredibly difficult to narrow down our top moments, since every guest brings such engaging and valuable conversations when talking about their epilepsy journey or their insight into various aspects of being a caregiver or living with epilepsy, but we did our best! As you watch or listen, be sure to go back and watch the full episode on talkaboutit.org, because we really are only skimming the surface of hours of incredible conversation. You did such a great job last year - keep up the great work with journaling, taking medication, getting good sleep and sustaining a good diet and exercise routine, and as always... keep TALKING ABOUT IT! These are some of the moments that we break down in this year-in-review: Epilepsy for Dummies - Elizabeth A. Thiele, MD, PhD, and Lauren Seeley Aguirre distill the entire world of epilepsy - from diagnosis, to treatment, to stigma and the challenges that arise - into one comprehensive book. This episode was incredibly popular, so we naturally had to cover it first! Tony Coelho shares his story of passing the ADA - Former House Representative Tony Coelho goes through his story of incredible persistence as he navigated the difficult hurdles of Congress and administrative pushback to get President George H.W. Bush to sign the ADA into law. He then kept up his spirits to keep battling after the Supreme Court rolled back much of what he fought for, and successfully got President George W. Bush to amend the legislation with a new bill in his favor. As a bonus, we also see Tony Coelho tell his story of standing up for what he believed is right... to the POPE! Sunflower Syndrome - Cal volleyball player Peyton DeJardin and Young Adults With Epilepsy member Abigayle Weitl each shared a story of their epilepsy journey in different episodes with incredibly similar details. Both were misdiagnosed as having a tick disorder when they were young due to an unconscious behavior of waving their fingers in front of their eyes when looking at the sun to trigger a seizure, and then both developed Jeavons syndrome as adults. We often say on this show that you'll never find a mirror, but if you search for your community, they are out there - no matter how rare your condition.  Conversations with your Care Team - Dr. Janet Greenwood and Dr. Barry Gidal each joined the podcast this year to answer questions for experts, and they both had great insight into the importance of being open and honest with your healthcare team and the importance of them being open and honest back. Self advocacy is so important, so be sure to keep a journal and write down questions ahead of time so that you make your doctor visits more efficient, and then take notes while in that meeting! Additionally, Dr. Gidal talks about the importance of checking your prescription before leaving the pharmacy to make sure it looks the same. Social Influencing - We see Jaime Simpson and Stanzi Potenza each talking about their social media profiles, and sharing the importance of using your platform to raise awareness about epilepsy. Let this be an inspiration for you to use whatever tools you have - it doesn't have to be social media - to advocate for others and share your story. Communities are so important in the world of epilepsy, so build yours with the thing you love to do! Alan Faneca - In Nick's personal favorite episode, former Pittsburgh Steeler and NFL Hall of Fame Inductee Alan Faneca joined the show to talk about his epilepsy journey, and being the dad of a daughter with epilepsy, as well. Speaking of using platforms for advocacy, Alan even included his epilepsy diagnosis in his Hall of Fame Induction speech to inspire others not to give up in the face of adversity.  And finally, we hear from Dr. Barry Gidal once more to hear about the positive future for epilepsy research.  Be inspired! Use your voice! Go into this year Talking About It and building our community! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks' shift to a royalty model for development funding and value creation, lessons learned from platform deals and cross-border R&D, the benefits of strong royalty agreements and backloaded milestone payments over headline upfronts, and industry dynamics for the coming year. Ken also shares insights from his deep experiences as a biotech investor and corporate director, and explains why scientific primacy should always drive biotech business decisions.         Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements and strategic movements shaping the future of healthcare.The pharmaceutical and biotech sectors are undergoing significant transformations, driven by scientific breakthroughs, regulatory developments, and strategic shifts. At the forefront is Eli Lilly's impressive lineup of investigational cardiometabolic drugs, spotlighted in Clarivate's "Drugs to Watch in 2026" report. This signals a robust focus on combating cardiometabolic disorders, which have vast implications for global health due to their widespread prevalence. The report also highlights Johnson & Johnson's competitive position in this therapeutic area, indicating a dynamic landscape where innovation is key.In oncology, Jazz Pharmaceuticals is making waves with its bispecific antibody, Ziihera, positioning it as a preferred HER2-targeted therapy for stomach cancer. This development marks a shift towards precision medicine and targeted therapies, which are gradually supplanting traditional treatments like Herceptin. The promising efficacy of Ziihera could revolutionize treatment protocols for HER2-positive gastric cancer patients, enhancing survival outcomes and quality of life.Meanwhile, a legal confrontation has erupted between Bayer and leading COVID-19 vaccine developers such as Moderna, Johnson & Johnson, and Pfizer-BioNTech. Bayer alleges patent infringement on intellectual property developed years prior. This lawsuit underscores the intricate relationship between innovation and intellectual property rights in the pharmaceutical industry, especially poignant in the aftermath of the COVID-19 pandemic.Daiichi Sankyo's collaboration with Genesis to commercialize Vanflyta—an acute myeloid leukemia treatment—across 13 European countries highlights strategic movements in oncology. Approved in 2023, this partnership exemplifies Daiichi's commitment to expanding its European market presence and improving patient access to critical cancer therapies.GSK's promising Phase 3 results for its hepatitis B drug candidate represent a potential breakthrough as a "functional cure." Such advancements could redefine management strategies for hepatitis B, a chronic infection affecting millions worldwide. The positive trial outcomes pave the way for FDA submission, showcasing GSK's dedication to addressing unmet medical needs through innovative approaches.Amgen's strategic partnership with Disco Pharmaceuticals illustrates ongoing investment in oncology research. With a $618 million agreement focused on cancer target discovery, Amgen leverages Disco's expertise to fortify its oncology pipeline. This collaboration underscores the significance of cooperative innovation in drug development and enhancing therapeutic options.In gene therapy, Ikarovec and VectorBuilder are advancing eye disease treatments through an innovative partnership. Their $1 billion deal aims to make gene therapies more accessible by enabling administration outside specialized settings—a transformative approach that could democratize advanced treatments.Hope Biosciences' Phase 2 study results offer hope for Parkinson's disease patients through stem cell therapy improvements in motor function. Despite some data discrepancies, these findings set the stage for Phase 3 trials and underscore the potential of stem cell therapies in neurological disorders.The pharmaceutical industry also grapples with economic challenges as layoffs rise by 16% year-over-year in 2025. Concurrently, despite regulatory hurdles and macroeconomic uncertainties, the FDA approved 55 new treatments and vaccines—a testament to resilience and innovation within biopharma.In regulatory dynamics, GSK's Exdensur received approval in Japan for treating severe asthma and chronic rhinosinusitisSupport the show

Happy Holidays and Happy New Year from your Talk About It family! We are closing an incredible year with a great episode that features people leading the charge from the next generation. The young adults who are receiving the torch to advocate for epilepsy awareness into the future! Greg chats with Abigayle Weitl and Chels Scantland from the Young Adults with Epilepsy organization that aims to provide young adults with resources to gain independence and break stigmas through education, awareness, mental health counseling, and so many incredible programs that they offer. They discuss each of their journeys with epilepsy and how they got involved in the organization, and how they have used their own experiences to impact the lives of the next generations. They also discuss tips for new years celebrations if you have epilepsy, strategies for preserving mental health in a social media world, and the importance of belonging when diagnosed with a condition like epilepsy. Greg then gives thanks for an incredible year we have had and sets his sights on the big things happening next year at Talk About It. We need your help! Like and share this episode, follow Talk About It on YouTube, and get involved in great organizations like Young Adults with Epilepsy! Have a safe and happy holiday season, and we will see you in the new year! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).Presenters:John Heymach, MD, PhDChair and ProfessorDepartment of Thoracic/Head and Neck Medical OncologyRuth Legett Jones Distinguished ChairMD Anderson Cancer CenterHouston, TexasSolange Peters, MD, PhD Professor and Director of Medical OncologyDepartment of OncologyUniversity Hospital of LausanneLausanne, SwitzerlandContent based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.Link to full program: https://bit.ly/3L1eksIGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome back to the Oncology Brothers podcast! In this episode, we continue the CME series on HER2-positive GEJ and gastric cancer, shifting focus to the essential topic of treatment toxicity management. We're joined by two leading experts: Dr. Geoffrey Ku from Memorial Sloan Kettering and Dr. Shruti Patel from Stanford University. Building on their previous discussion of upper GI treatment algorithm with Dr. Rutika Mehta, this episode delves into the practical realities of managing patients on complex regimens. Drs. Ku & Patel break down the side effect profiles across the treatment continuum—from frontline trastuzumab-based combinations to emerging therapies like zanidatamab—and provide actionable strategies for community oncologists. Episode Highlights: • Practical management of frontline side effects with FOLFOX/XELOX chemotherapy plus trastuzumab and pembrolizumab • Reality check on trastuzumab cardiotoxicity: incidence rates and monitoring protocols in gastric vs. breast cancer • Immune-related adverse events with checkpoint inhibitors: what's common vs. rare in GI cancers • Critical insights on zanidatamab's synergistic diarrhea toxicity and mandatory prophylaxis strategies • TDXd (Enhertu) in second-line: moving beyond ILD fears to address frequent cytopenias and marrow management • Expert consensus on infusion reaction management for novel biologics • The importance of managing baseline symptoms in patients with dysphagia and nausea This episode bridges the gap between trial data and clinical practice, offering real-world wisdom on keeping patients on effective therapies through proactive toxicity management. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for our complete CME series covering treatment algorithms, FDA approvals, and practical management strategies! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/navigating-the-adverse-event-landscape-in-her2-gea-therapy

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease. Episode Highlights: • Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings. • Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options. • Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status. • The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions. • Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape. • Considerations for managing side effects and the importance of treatment sequencing in palliative care. Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications    #HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME

Take a seat on the couch. Take some space. Tell us what's on your mind. This episode is all about therapy! Greg is relatively new to the world of therapy, and there is no guest more fitting to have on this week's episode than his personal therapist Brian Wry! Brian is a licensed marriage and family therapist with his own practice, and he has some great insight into the importance of therapy for anybody, including those affected by epilepsy - whether you are a patient or a caregiver. They discuss how to find a therapist and the patience that it may require, finding a reset for your mind, the nature of human interaction having a positive impact on physiology and the risks of people using resources like Chat GPT as therapy in order to save money. Plus, Greg walks us through the process of creating his "Ticket Bowls" and the value that they have beyond looking really cool! Do not miss this episode, it is so important for you to get your mind right! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

This episode, Heather and Seth record at the NCLifeSci 2025 Annual Meeting with Tom Croce, Vice President of Global Patient Advocacy and Engagement at Jazz Pharmaceuticals. Tom shares how his team integrates patient perspectives across the entire drug development and commercialization process, and why “patient centricity” is transforming the pharmaceutical industry. We explore the growing role of patient input in clinical trials, the future of advocacy-driven innovation, and more. Tune in for an insightful discussion on building better treatments by listening to the people who need them most.

From all of us at Talk About It!, HAPPY THANKSGIVING! This week, we are SERVING up a very special episode that will make you want seconds - an incredible story to watch or listen to while you prep your holiday dinner! Greg chats with Peyton DeJardin, a senior at University of California Berkeley and a force on the volleyball court. When she was just a young girl, she developed a self-induced photosensitive epilepsy or "sunflower syndrome" which later turned into Jeavons syndrome which would sometimes cause upwards of 100 small seizures per day. It took years to correctly diagnose her condition as epilepsy, but despite her diagnosis, she has never let it get in her way. Her competitive spirit and positive attitude make her a volleyball star at Cal, and her awareness and resolve help her to inform others about her condition and point out ways in which environments might trigger her or others to have seizures so that changes can be made. They discuss how lighting can be a trigger for photosensitive epilepsy and how she spreads awareness about that in class or on the court, and her epilepsy journey through being a young kid into her adulthood. Greg also revisits a previous interview about Helmets 4 Helmets because of their UC Berkeley connection, and gives many thanks for Thanksgiving along with tips on how to talk about epilepsy at the dinner table this holiday. Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Happy Epilepsy Awareness Month from Talk About It! As the title says, this month is all about making people aware of epilepsy and what to do if you see someone having a seizure. Remember... STAY - Remain with the person until they are awake and alert. SAFE - Keep the person safe and move them away from harm. SIDE - Turn the person on their side and put something soft under their head. For this very special episode, we are talking about something that is SO IMPORTANT but is rarely shared with new parents, febrile seizures. Greg brings on his good friend Trevor Gretzky to share their terrifying story about his daughter having a febrile seizure, and having no idea what was happening or why. How is it possible that young parents aren't prepared for this given how common it is, and how can we all get the message out about febrile seizures? It starts with, you guessed it, talking about it! Do not miss this episode, this is SO important. Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Boo! Welcome to the first Halloween Special from Talk About It! This episode is all treats and no tricks. Greg sits down with his good friend who has his fair share of people dressing as his characters for trick-or-treating or Halloween festivities - actor Jeff Daniel Phillips! Jeff has done everything from being the Geico caveman on all of our screens to Herman Munster in Rob Zombie's remake of the classic spooky family, and he joins the podcast to talk about a new project that he wrote, directed and starred in called Cursed in Baja. The movie centers around his character that takes a trip to Mexico in search of his fortune, but has seizure-like episodes that take him into another scary world. They talk about portraying seizures on screen and the best ways to go about those scenes, and the positive and negative examples of that being done. Also, they talk about Halloween, Jeff's work with Rob Zombie, tips for celebrating Halloween when you have epilepsy or are a caregiver to someone with epilepsy, and of COURSE.... the Geico Caveman. This episode is so much fun, you don't want to miss it! Have a safe and happy Halloween, everybody! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Welcome to part two of embracing our dummy-ness! In this episode, Greg continues the conversation with Dr. Elizabeth Thiele, a neurologist and epileptologist, and Lauren Aguirre, an author, journalist, epilepsy patient and caregiver to her children that also have epilepsy. They authored the next installment of the incredibly popular "For Dummies" series of books from Wiley, and their book "Epilepsy for Dummies" will be everywhere books are sold at the end of the month, but you can pre-order or download it in digital formats NOW! In this part two, they discuss looking at epilepsy from the perspective of both the patient and the medical professional which really helped them take a wholistic look at the condition for the book, the ketogenic diet, all of the valuable information that can be found within the book, new research in TSC, and stick around for the end because they take rapid fire questions from Greg about epilepsy and caregiving. There is so much valuable information in this episode, which is just a taste of what you will find within the pages of their new book. Seriously, folks, whether you are a patient with epilepsy, a caregiver, an educator, or just a good citizen, you NEED to get your copy!  Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner: